Friday, September 16, 2016

Yaz


Yaz is a brand name of drospirenone/ethinyl estradiol, approved by the FDA in the following formulation(s):


YAZ (drospirenone; ethinyl estradiol - tablet; oral)



  • Manufacturer: BAYER HLTHCARE

    Approval date: March 16, 2006

    Strength(s): 3MG;0.02MG [RLD][AB]

Has a generic version of Yaz been approved?


A generic version of Yaz has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Yaz and have been approved by the FDA:


DROSPIRENONE AND ETHINYL ESTRADIOL (drospirenone; ethinyl estradiol tablet; oral)



  • Manufacturer: BARR

    Approval date: March 30, 2009

    Strength(s): 3MG;0.02MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: November 28, 2011

    Strength(s): 3MG;0.02MG [AB]

LORYNA (drospirenone; ethinyl estradiol tablet; oral)



  • Manufacturer: SANDOZ

    Approval date: March 28, 2011

    Strength(s): 3MG;0.02MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Dihydrospirorenone as an antiandrogen
    Patent 5,569,652
    Issued: October 29, 1996
    Inventor(s): Beier; Sybille & Elger; Walter & Nishino; Yukishige & Wiechert; Rudolf
    Assignee(s): Schering Aktiengesellschaft
    Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for treatment of androgen-induced disorders and/or for contraception.
    Patent expiration dates:

    • October 29, 2013
      ✓ 
      Patent use: PREVENTION OF PREGNANCY




  • Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol
    Patent 5,798,338
    Issued: August 25, 1998
    Inventor(s): Backensfeld; Thomas & Tack; Johannes
    Assignee(s): Schering Aktiengesellschaft
    A method and pharmaceutical compositions are disclosed for reducing oxidative degradation of 17 .alpha.-ethinylestradiol comprising combining the estradiol with an effective amount of cyclodextrin, thus forming a cyclodextrin clathrate of the steroid.
    Patent expiration dates:

    • July 10, 2015
      ✓ 
      Drug product




  • Pharmaceutical composition for use as a contraceptive
    Patent 6,787,531
    Issued: September 7, 2004
    Inventor(s): Juergen; Hilman & Wolfgang; Heil & Ralph; Lipp & Renate; Heithecker & Michael; Huempel & Johannes W.; Tack
    Assignee(s): Schering AG
    A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
    Patent expiration dates:

    • August 31, 2020
      ✓ 
      Drug product




  • PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDR
    Patent 6,933,395
    Issued: August 23, 2005
    Inventor(s): Mohr; Jörg-Thorsten & Nickisch; Klaus
    Assignee(s): Schering AG
    Process for the production of drospirenone (6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, DRSP) (1) and 7α-(3-hydroxy-1-propyl)-6β,7β; 15β,16β-dimethylene-5β-androstane-3β,5,17β-triol (ZK 92836) and 6β,7β; 15β,16β-dimethylene-5β-hydroxy-3-oxo-17α-androstane-21,17-carbolactone (ZK 90965) as intermediate products of the process.
    Patent expiration dates:

    • August 11, 2017
      ✓ 
      Drug product




  • Cyclodextrin-drospirenone inclusion complexes
    Patent 6,958,326
    Issued: October 25, 2005
    Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
    Assignee(s): Schering AG
    Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
    Patent expiration dates:

    • December 20, 2021
      ✓ 
      Drug product




  • Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
    Patent 6,987,101
    Issued: January 17, 2006
    Inventor(s): Nashed; Norman
    Assignee(s): Schering Aktiengesellschaft
    A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.
    Patent expiration dates:

    • December 22, 2017
      ✓ 
      Patent use: TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER




  • Compositions of estrogen-cyclodextrin complexes
    Patent 7,163,931
    Issued: January 16, 2007
    Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
    Assignee(s): Schering Aktiengesellchaft
    Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
    Patent expiration dates:

    • December 20, 2021
      ✓ 
      Patent use: PREVENTION OF PREGNANCY




  • Composition for contraception
    Patent RE37564
    Issued: February 26, 2002
    Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
    Assignee(s): Schering Aktiengesellschaft
    A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Patent expiration dates:

    • June 30, 2014
      ✓ 
      Drug product




  • Composition for contraception
    Patent RE37838
    Issued: September 10, 2002
    Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
    Assignee(s): Schering Aktiengesellschaft
    A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Patent expiration dates:

    • June 30, 2014
      ✓ 
      Drug product




  • Composition for contraception
    Patent RE38253
    Issued: September 16, 2003
    Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
    Assignee(s): Schering Aktiengesellschaft
    A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Patent expiration dates:

    • June 30, 2014
      ✓ 
      Drug product



See also...

  • Yaz Consumer Information (Drugs.com)
  • YAZ Consumer Information (Wolters Kluwer)
  • Yaz Consumer Information (Cerner Multum)
  • YAZ Advanced Consumer Information (Micromedex)
  • Drospirenone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
  • Drospirenone and ethinyl estradiol Consumer Information (Cerner Multum)
  • Yaz 28 Advanced Consumer Information (Micromedex)
  • Drospirenone and ethinyl estradiol Advanced Consumer Information (Micromedex)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)